Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.
patent: 3169966 (1965-02-01), Schmidt et al.
patent: 6403610 (2002-06-01), Malleron et al.
patent: 2004/0058919 (2004-03-01), Bacque et al.
patent: 2004/0087619 (2004-05-01), Bacque et al.
patent: 2006/0040949 (2006-02-01), Surivet et al.
patent: 2006/0205719 (2006-09-01), Hubschwerlen et al.
patent: WO 00/21952 (2000-04-01), None
patent: WO 01/07433 (2001-02-01), None
patent: WO 02/08224 (2002-01-01), None
patent: WO 02/24684 (2002-03-01), None
patent: WO 02/50040 (2002-06-01), None
patent: WO 02/50061 (2002-06-01), None
patent: WO 02/056882 (2002-07-01), None
patent: WO 03/064421 (2003-08-01), None
patent: WO 03/064431 (2003-08-01), None
patent: WO 2004/024712 (2004-03-01), None
patent: WO 2004/035569 (2004-04-01), None
patent: WO 2004/041210 (2004-05-01), None
patent: WO 2004/058144 (2004-07-01), None
patent: WO 2004/087145 (2004-10-01), None
patent: WO 2004/089947 (2004-10-01), None
F.Z. Dorwald “Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design” 2005, Wiley-VCH Verlag GmbH & Co. KGaA, Wienheim.
Amábile-Cuevas, C.F. New Antibiotics and New Resistance. Amer. Scientist 2003, 91, 138-149.
Berge, S.M. et al. Pharmaceutical Salts. J. Pharm. Sci. 1977, 66, 1-19.
Correa, A. et al. Novel Alternative for the N-N Bond Formation through a PIFA-Mediated Oxidative Cyclization and Its Applicaton to the Synthesis of Indazo-3-ones. J. Org. Chem. 2006, 71, 3501-3505.
Sanders, Jr., W.E. et al. Inducible Beta-lactamases: Clinical and Epidemiologic Implications for the Use of Newer Cephalosporins. Reviews of Infectious Diseases 1988, 10(4), 830-838.
International Search Report dated Sep. 1, 2006 for corresponding Appln. No. PCT/US06/11631.
Gaut PL. et al. “Intravenous/oral Ciprofloxacin Therapy Versus Intravenous Ceftazidime Therapy for Selected Bacterial Infections” American Journal of Medicine, 1989, 87(5A),169S-175S.
Gomez L. et al. “Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis” Bioorganic & Medicinal Chemistry Letters, 2007, 17(10), 2723-7.
Nagakura, M. et al. “Synthesis and Antiinflammatory Actions of 4,5,6,7-Tetrahydro Indazole-5-carboxylic Acids” Journal of Medicinal Chemistry, 1979, 22(1), 48-52.
Nicolaus et al. “Symbiotic Approach to Drug Design” Decision Making in Drug Research, 1983, pp. 173-186.
Wiener J. et al. “Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains” Bioorganic & Medicinal Chemistry Letters, 2007, 17(10), 2718-22.
European Extended Search Report dated Feb. 3, 2010 for European Appln. No. 06748931.0.
Allison Brett D.
Grice Cheryl A.
Hack Michael D.
Santillan, Jr. Alejandro
Andres Janet L.
Janssen Pharmaceutica NV
Bicyclic pyrazole compounds as antibacterial agents does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with Bicyclic pyrazole compounds as antibacterial agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic pyrazole compounds as antibacterial agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226116